FNY Partners Fund’s Puma Biotechnology PBYI Stock Holding History

FNY Partners Fund’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-750	Closed	-$69.8K	–	682
2017 Q2	$65K	Buy	750 +250	+50%	+$14K	0.02%	247
2017 Q1	$18K	Buy	+500	New	+$18.2K	﹤0.01%	976

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FNY Partners Fund's PBYI Position: Q3 2017 in Review

FNY Partners Fund sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 750 shares — an estimated $69.8K sold.

FNY Partners Fund first reported a position in PBYI in Q1 2017 and held it in 2 quarters. The position peaked at $65K in Q2 2017. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

FNY Partners Fund reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
FNY Partners Fund sold 750 Puma Biotechnology shares in Q3 2017, an estimated $69.8K.
FNY Partners Fund first reported a position in Puma Biotechnology in Q1 2017 and held it in 2 quarters.
FNY Partners Fund's Puma Biotechnology position peaked at $65K in Q2 2017.
171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.